FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108173793> ?p ?o ?g. }

• W2108173793 endingPage "1212" @default.
• W2108173793 startingPage "1208" @default.
• W2108173793 abstract "The combination of cisplatin or carboplatin and etoposide is the standard treatment for certain poorly differentiated neuroendocrine cancers, such as small‑cell lung cancer. The aim of this study was to assess the efficacy and tolerability of the carboplatin‑etoposide regimen in metastatic castration‑resistant prostate cancer (mCRPC). A total of 27 patients treated by carboplatin [area under the curve (AUC)=5] and etoposide (100 mg/m² intravenous infusion on days 1-3 or 75 mg orally̸day for 10 days) for mCRPC were included for analysis. The median progression‑free survival was 3.3 months [95% confidence interval (CI): 1.9‑4.2] and the median overall survival (OS) was 8.1 months (95% CI: 4.06‑12.36). The main grade 3‑4 toxicities were haematological, namely anemia (33.3%), neutropenia (25.9%) and thrombocytopenia (22.2%), whereas the most common non‑hematological toxicity was asthenia (22.2%). The efficacy, compliance and safety profile were generally similar between the oral and intravenous etoposide groups. Pretreated patients with mCRPC may benefit from the carboplatin‑etoposide regimen in terms of OS. The toxicities were acceptable, without reported treatment‑related mortality. Therefore, the oral etoposide regimen may be an viable alternative for improving the quality of life of the patients. However, this regimen requires further prospective investigation to confirm its efficacy." @default.
• W2108173793 created "2016-06-24" @default.
• W2108173793 creator A5000284560 @default.
• W2108173793 creator A5003798935 @default.
• W2108173793 creator A5017307401 @default.
• W2108173793 creator A5032645505 @default.
• W2108173793 creator A5033357246 @default.
• W2108173793 creator A5039923190 @default.
• W2108173793 creator A5065018863 @default.
• W2108173793 creator A5066804923 @default.
• W2108173793 creator A5067565814 @default.
• W2108173793 creator A5075171938 @default.
• W2108173793 creator A5079351370 @default.
• W2108173793 date "2015-08-31" @default.
• W2108173793 modified "2023-09-26" @default.
• W2108173793 title "Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study" @default.
• W2108173793 cites W1967197291 @default.
• W2108173793 cites W1978781087 @default.
• W2108173793 cites W2019607817 @default.
• W2108173793 cites W2052858101 @default.
• W2108173793 cites W2063116472 @default.
• W2108173793 cites W2083876618 @default.
• W2108173793 cites W2087800680 @default.
• W2108173793 cites W2106315111 @default.
• W2108173793 cites W2106787323 @default.
• W2108173793 cites W2117994949 @default.
• W2108173793 cites W2123838638 @default.
• W2108173793 cites W2144110960 @default.
• W2108173793 cites W2146428704 @default.
• W2108173793 cites W2148643283 @default.
• W2108173793 cites W2157092239 @default.
• W2108173793 cites W2157976596 @default.
• W2108173793 cites W2158011521 @default.
• W2108173793 cites W2161546209 @default.
• W2108173793 cites W2167331614 @default.
• W2108173793 doi "https://doi.org/10.3892/mco.2015.628" @default.
• W2108173793 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4665308" @default.
• W2108173793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26807222" @default.
• W2108173793 hasPublicationYear "2015" @default.
• W2108173793 type Work @default.
• W2108173793 sameAs 2108173793 @default.
• W2108173793 citedByCount "11" @default.
• W2108173793 countsByYear W21081737932018 @default.
• W2108173793 countsByYear W21081737932019 @default.
• W2108173793 countsByYear W21081737932020 @default.
• W2108173793 countsByYear W21081737932021 @default.
• W2108173793 countsByYear W21081737932022 @default.
• W2108173793 countsByYear W21081737932023 @default.
• W2108173793 crossrefType "journal-article" @default.
• W2108173793 hasAuthorship W2108173793A5000284560 @default.
• W2108173793 hasAuthorship W2108173793A5003798935 @default.
• W2108173793 hasAuthorship W2108173793A5017307401 @default.
• W2108173793 hasAuthorship W2108173793A5032645505 @default.
• W2108173793 hasAuthorship W2108173793A5033357246 @default.
• W2108173793 hasAuthorship W2108173793A5039923190 @default.
• W2108173793 hasAuthorship W2108173793A5065018863 @default.
• W2108173793 hasAuthorship W2108173793A5066804923 @default.
• W2108173793 hasAuthorship W2108173793A5067565814 @default.
• W2108173793 hasAuthorship W2108173793A5075171938 @default.
• W2108173793 hasAuthorship W2108173793A5079351370 @default.
• W2108173793 hasBestOaLocation W21081737931 @default.
• W2108173793 hasConcept C126322002 @default.
• W2108173793 hasConcept C141071460 @default.
• W2108173793 hasConcept C143998085 @default.
• W2108173793 hasConcept C197934379 @default.
• W2108173793 hasConcept C2776694085 @default.
• W2108173793 hasConcept C2777063308 @default.
• W2108173793 hasConcept C2778119113 @default.
• W2108173793 hasConcept C2778239845 @default.
• W2108173793 hasConcept C2778375690 @default.
• W2108173793 hasConcept C2778850193 @default.
• W2108173793 hasConcept C2781413609 @default.
• W2108173793 hasConcept C2781451048 @default.
• W2108173793 hasConcept C71924100 @default.
• W2108173793 hasConceptScore W2108173793C126322002 @default.
• W2108173793 hasConceptScore W2108173793C141071460 @default.
• W2108173793 hasConceptScore W2108173793C143998085 @default.
• W2108173793 hasConceptScore W2108173793C197934379 @default.
• W2108173793 hasConceptScore W2108173793C2776694085 @default.
• W2108173793 hasConceptScore W2108173793C2777063308 @default.
• W2108173793 hasConceptScore W2108173793C2778119113 @default.
• W2108173793 hasConceptScore W2108173793C2778239845 @default.
• W2108173793 hasConceptScore W2108173793C2778375690 @default.
• W2108173793 hasConceptScore W2108173793C2778850193 @default.
• W2108173793 hasConceptScore W2108173793C2781413609 @default.
• W2108173793 hasConceptScore W2108173793C2781451048 @default.
• W2108173793 hasConceptScore W2108173793C71924100 @default.
• W2108173793 hasIssue "6" @default.
• W2108173793 hasLocation W21081737931 @default.
• W2108173793 hasLocation W21081737932 @default.
• W2108173793 hasLocation W21081737933 @default.
• W2108173793 hasLocation W21081737934 @default.
• W2108173793 hasOpenAccess W2108173793 @default.
• W2108173793 hasPrimaryLocation W21081737931 @default.
• W2108173793 hasRelatedWork W1975956559 @default.
• W2108173793 hasRelatedWork W1989051367 @default.
• W2108173793 hasRelatedWork W1991613108 @default.
• W2108173793 hasRelatedWork W2013123615 @default.

• next